Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.16 | N/A | +54.67% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.16 | N/A | +54.67% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about the company's future. They noted advancements in their drug development pipeline.
Management highlighted progress in their pipeline despite the loss.
They emphasized the importance of upcoming clinical trials.
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which is a positive sign for investors. However, the stock fell by 2.08%, likely due to a lack of revenue information and no guidance for the future. Investors may be concerned about the absence of specific future plans, despite the EPS beat.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MASCO CORP
Feb 14, 2011